July 23, 2017 9:43 PM ET


Company Overview of Teva Pharmaceuticals USA, Inc.

Company Overview

Teva Pharmaceuticals USA, Inc. manufactures and markets generic drugs in the United States. It offers generic products for various therapeutic options, such as cardiovascular, anti-infective, central nervous system, anti-inflammatory, oncolytic, anti-diabetic, analgesic, dermatologic, respiratory, and women’s health. The company offers its products in various dosage forms, such as tablets, capsules, injectables, creams, ointments, inhalants, solutions, and suspensions. It serves patients through distributors. Teva Pharmaceuticals USA, Inc. was formerly known as Lemmon Pharmacal Company and changed its name to Teva Pharmaceuticals USA, Inc. in 1996. The company was founded in 1945 and is base...

1090 Horsham Road

North Wales, PA 19454

United States

Founded in 1945





Key Executives for Teva Pharmaceuticals USA, Inc.

Vice President of Government Affairs
Vice President of Government Affairs
Vice President of Government Affairs
Vice President of Government Affairs
Compensation as of Fiscal Year 2017.

Teva Pharmaceuticals USA, Inc. Key Developments

Wockhardt Limited, Wockhardt UK Holding Limited and CP Pharamaceuticals Limited Settle Commercial Litigation in the High Court, London with Teva Pharmaceuticals USA, Inc. and Cephalon Inc

Wockhardt Limited announced that, WL and two subsidiaries, Wockhardt UK Holding Limited and CP Pharamaceuticals Limited, in the United Kingdom have settled an ongoing commercial litigation before the High Court in London, United Kingdom in relation to supply contract for a drug named Trisenox. The dispute between the parties was in respect of the price charged by CP to its counterparty to the contract, Cephalon Inc, (Cephalon) an affiliate of Teva Pharmaceuticals USA, Inc. (Teva). The proceedings commenced in September 2015. Under the referred settlement between the parties, CP has agreed to waive its claim for the outstanding trade receivable of GBP 20 million and accordingly dropped its counterclaim for the said amount and further paid a sum of GBP 23 million to Teva and Cephalon by way of full and final settlement of Teva’s claims. The High Court has accepted the settlement between the parties and a Consent Order was issued on June 21, 2017.

Teva Pharmaceuticals USA, Inc. Extends Voluntary Nationwide Recall to Consumer/User Level for One Lot of Paliperidone ER Tablets, 3mg, 90 Count Bottles

Teva Pharmaceuticals USA, Inc. initiated a voluntary recall to retail-level on May 31, 2017 for one lot of Paliperidone Extended-Release Tablets, 3mg, 90 count bottles that was distributed under the Actavis Pharma Inc. label. In coordination with FDA, Teva is extending this recall to the CONSUMER/USER level. This recall is being carried out due to failing test results for dissolution. Teva cannot at this time exclude the potential for additional tablets to be below specification. Paliperidone Extended Release Tablets, 3mg is indicated for the treatment of schizophrenia and schizoaffective disorders and was distributed Nationwide in the USA to wholesalers. Taking a product for the treatment of schizophrenia and schizoaffective disorders that has failed dissolution could result in less drug being absorbed. If two or more consecutive dosing regimens are with affected product, a failure to maintain therapeutic levels could occur, which could reduce effectiveness in treating a patient’s mental and/or mood symptoms, including suicidal thoughts and behavior, self-injurious behavior, mental hospitalizations, assaults, aggressive behavior, as well as vocal and motor tics. Based on Teva’s investigation, the likelihood of consuming two or more consecutive doses with affected product is low. In addition, no post marketing adverse events have been received to date for lack of effectiveness for this recalled lot.

Teva Pharmaceuticals USA, Inc Wins $242,958,271.20 Federal Contract

Teva Pharmaceuticals USA Inc. has won a $242,958,271.20 federal contract from the U.S. Department of Veterans Affairs' National Acquisition Center for the supply of albuterol sulfate 90 microgram/actuat inhalers.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

August 23, 2016
Frank W. Kerr Inc.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Teva Pharmaceuticals USA, Inc., please visit www.tevausa.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.